FDA Approves Pembrolizumab for Patients with Non-Small Cell Lung Cancer



The FDA has approved the drug pembrolizumab to treat patients with advanced non-small cell lung cancer (NSCLC) whose tumors express a protein called PD-L1.



Source link

Comments are closed.